What insurance policy changes affect code R53.82?

There are 9 tracked policy changes affecting code R53.82, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code R53.82?

Payers that have issued tracked updates for code R53.82 include: Aetna.

How do I get notified when code R53.82 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code R53.82. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code R53.82?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

R53.82 Insurance Policy Changes

ICD-10 R53.82 is officially defined as "Chronic fatigue, unspecified." code R53.82 is referenced in 9 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code R53.82 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Sep 29, 2026Medium impact
Adoptive Immunotherapy and Cellular Therapy (CPB 0641, reviewed 2026-09-25)
Aetna considers adoptive immunotherapy using tumor-infiltrating lymphocytes (TILs) or interleukin-2 activated lymphokine-activated killer (LAK) cells experimental, investigational or unproven for a long list of indications, including Alzheimer disease, esophageal, gynecologic, head and neck, hepatocellular, lung, glioblastoma, renal cell, pancreatic and other malignancies, because there is not adequate evidence that it is more beneficial than IL-2 alone. Melanoma is excluded from that list for lifileucel (Amtagvi), an FDA-approved TIL therapy. Cellular therapy (including embryonic cell, fresh cell, glandular, live cell, MAGE-A4 cell, organotherapy and xenotransplant therapy) is considered experimental, investigational or unproven for a long list of indications due to lack of adequate evidence, including angina, arthritis, diabetes, heart failure, hypertension, ischemic heart disease, ischemic stroke, motor neuron diseases, osteoarthritis and focal cartilage defects of the knee, peripheral arterial disease, and traumatic brain injury. Cancer is excluded from that list for afamitresgene autoleucel (Tecelra), an FDA-approved MAGE-A4-directed TCR T-cell therapy for synovial sarcoma. The policy also lists CAR T-cell therapy for solid tumors and virus-specific T-cell lymphocyte therapy for viral infections as experimental, investigational or unproven. HCPCS code S2107 (adoptive immunotherapy per course of treatment) and M0075 (cellular therapy) are listed as not covered for the indications in the policy.
Aetna · Identified Aug 19, 2026Medium impact
Neuropsychological and Psychological Testing (CPB 0158, reviewed 2026-03-20)
Aetna covers neuropsychological testing when it is needed to assess cognitive impairment due to medical or psychiatric conditions, provided the hours or units requested do not exceed the reasonable time needed to address the clinical questions, the testing techniques are validated for the proposed diagnostic question and for the member's age and population, and the testing does not repeat measurements of the same domain. Neuropsychological testing requested for a mental health diagnosis is considered for coverage through the mental health benefit, and testing requested for a medical diagnosis such as traumatic brain injury, stroke, epilepsy or Alzheimer's disease is considered under the medical benefit. Testing performed for educational, employment, disability qualification or legal or court-related purposes is not covered, and computerized neuropsychological assessment devices such as Cognitrax are considered experimental for screening asymptomatic people and for other indications, including screening and monitoring multiple sclerosis-related cognitive impairment.
Aetna · Identified Aug 18, 2026Medium impact
Nutritional Counseling (CPB 0049, reviewed 2026-03-10)
Aetna considers nutritional counseling a medically necessary preventive service for children and adults who are obese, and for adults who are overweight and have hypertension, dyslipidemia, impaired fasting glucose, or metabolic syndrome, when a provider recognized under the plan furnishes it. Aetna also considers counseling medically necessary for other chronic conditions where dietary adjustment has a therapeutic role, including diabetes, eating disorders, gastrointestinal disorders, hypertension, kidney disease, and seizures (ketogenic diet). Aetna considers counseling of unproven value for asthma, attention-deficit hyperactivity disorder, and chronic fatigue syndrome, and considers the NutrEval test experimental, investigational, or unproven.
Aetna · Identified Aug 16, 2026Medium impact
Lyme Disease and other Tick-Borne Diseases (CPB 0215, reviewed 2026-07-21)
Aetna considers outpatient IV antibiotic therapy medically necessary for Lyme disease only when the clinical presentation is compatible with the disease and supported by two-tier serologic testing. Once Lyme disease is definitively diagnosed, an initial 4-week course of outpatient IV antibiotic therapy is medically necessary for persistent Lyme arthritis after failing a 4-week course of oral antibiotics, for moderate-to-severe cardiac or neurologic involvement, and for specified cases in pregnant women, and one repeat 4-week course is medically necessary with objective evidence of relapse, progression of organ damage, or a new focus or type of organ damage. Aetna considers IV antibiotic therapy for early Lyme disease, additional antibiotic therapy for post-treatment persistently fatigued patients, and a range of listed tests and treatments experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Complementary and Alternative Medicine (CPB 0388, reviewed 2026-06-25)
Aetna covers alternative medicine interventions when they are supported by adequate evidence of safety and effectiveness in the peer-reviewed published medical literature, subject to benefit plan limitations and exclusions. Acupuncture, biofeedback, chelation therapy, chiropractic services and electrical stimulation are addressed under separate Aetna policies. Many other interventions are listed as experimental, investigational or unproven, including intravenous micronutrient therapy (Myers' Cocktail), Gua Sha, colon hydrotherapy and the Patricia Kane protocol, and standard benefit plans exclude nutritional supplements and medical marijuana.
Aetna · Identified Aug 14, 2026Medium impact
Attended Electroencephalographic (EEG) Video Monitoring (CPB 0322, reviewed 2026-06-08)
Aetna considers attended electroencephalographic (EEG) video monitoring performed in a healthcare facility medically necessary when diagnosis remains uncertain after neurological examinations and standard EEG studies within the past 90 days, non-neurological causes such as syncope or cardiac arrhythmias have been ruled out, and documentation shows that extended ambulatory EEG monitoring as an outpatient would not be sufficient for the member's needs. Covered indications include differentiating epileptic events from psychogenic seizures, establishing the specific type of epilepsy in poorly characterized seizure types, establishing the diagnosis of epilepsy and evaluating response to treatment in children 3 years of age or younger, children with severe cognitive deficits, and older persons unable to communicate due to disability, evaluating newborns with proven or suspected acute brain injury and co-morbid encephalopathy, and identifying a seizure focus in members with intractable epilepsy who are being considered for epilepsy surgery. Monitoring longer than 7 days is medically necessary when events are so infrequent that they would likely not be detected within one week, when an extended stay is needed for care of an adverse event, or when medication adjustments require ongoing monitoring that cannot be safely performed on an outpatient basis. Once the cause of seizures and the specific type of epilepsy have been established, continued video EEG monitoring in older children and adults is considered not medically necessary. Attended EEG video monitoring for medical clearance to operate a motor vehicle is not considered medically necessary, and it is considered experimental, investigational or unproven for other indications including obstructive sleep apnea, assessment of the effectiveness of drug treatment in epilepsies, amyotrophic lateral sclerosis, cardiac arrest, chronic fatigue, coma, diagnosis of brain death, encephalopathy and headache.
Aetna · Identified Aug 14, 2026Medium impact
Eagle's and Ernest Syndrome (CPB 0400, reviewed 2026-06-30)
Aetna's Clinical Policy Bulletin 0400 considers styloidectomy medically necessary for Eagle's syndrome only when specific criteria are met, with separate criteria for the non-vascular form and the vascular form linked to carotid artery dissection. Radiofrequency thermoneurolysis is considered experimental, investigational or unproven for Eagle's and Ernest syndromes, and styloidectomy for jugular vein stenosis, for carotid stenosis without dissection, and for other listed indications such as tinnitus, headache and neck pain is also considered experimental, investigational or unproven.
Aetna · Identified Aug 12, 2026Medium impact
Adoptive Immunotherapy and Cellular Therapy (CPB 0641, reviewed 2025-10-01)
Aetna's Clinical Policy Bulletin 0641 considers adoptive immunotherapy using tumor-infiltrating lymphocytes or IL-2-activated LAK cells, and a broad list of cellular therapies, experimental, investigational or unproven for the indications it names. Those indications include most cancers, Alzheimer disease, COVID-19, heart failure, ischemic heart disease, orthopedic and musculoskeletal disorders, and minimization of general immunosuppression in kidney transplant recipients. The policy names exceptions for lifileucel (Amtagvi) in melanoma and afamitresgene autoleucel (Tecelra) in synovial sarcoma, and it lists CAR T-cell therapy for solid tumors and virus-specific T-cell lymphocyte therapy for viral infections among the unproven uses.
Aetna · Identified Oct 17, 2026Low impact
Electrical Stimulation for Nausea, Vomiting, Motion Sickness and Other Selected Indications (CPB 0676, reviewed 2026-10-07)
Aetna clinical policy bulletin 0676 (reviewed October 7, 2026) covers prescription ReliefBand and PrimaBella devices for post-operative or chemotherapy-induced nausea that does not respond to antiemetics and conservative care, and for hyperemesis gravidarum that does not respond to conservative therapy. It treats other transcutaneous acupoint stimulation uses, such as motion sickness, autism, dysmenorrhea and fertility, as experimental, and does not cover over-the-counter disposable ReliefBand devices. The source gives a review date but no effective date.

Watch R53.82

Get one email when a payer policy names R53.82, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Adoptive Immunotherapy and Cellular Therapy (CPB 0641, reviewed 2026-09-25)

Neuropsychological and Psychological Testing (CPB 0158, reviewed 2026-03-20)

Nutritional Counseling (CPB 0049, reviewed 2026-03-10)

Lyme Disease and other Tick-Borne Diseases (CPB 0215, reviewed 2026-07-21)

Complementary and Alternative Medicine (CPB 0388, reviewed 2026-06-25)

Attended Electroencephalographic (EEG) Video Monitoring (CPB 0322, reviewed 2026-06-08)

Eagle's and Ernest Syndrome (CPB 0400, reviewed 2026-06-30)

Adoptive Immunotherapy and Cellular Therapy (CPB 0641, reviewed 2025-10-01)

Electrical Stimulation for Nausea, Vomiting, Motion Sickness and Other Selected Indications (CPB 0676, reviewed 2026-10-07)

What insurance policy changes affect code R53.82?

Which payers have updated policy for code R53.82?

How do I get notified when code R53.82 policy changes?

Why do payers change policies for code R53.82?